These events provide an opportunity to present ExpreS2ion’s technology platform and development pipeline to investors and industry participants. More details, including event registration information, are available on the Company’s website and via the links below. To arrange a meeting at these events, please contact us at partnering@expres2ionbio.com or investor@expres2ionbio.com.

4-5 March 2026 | Sachs Associates: European Life Sciences CEO Forum
Zurich, Switzerland
ExpreS2ion will participate in the 19th European Life Sciences Forum (ELSF), an international partnering and investor conference.

CFO Keith Alexander will present ExpreS2ion at 12:10 CET on 5 March 2026, focusing on the ES2B-C001 breast cancer vaccine program. In addition to the presentation, he will engage in one-on-one meetings with institutional investors, pharmaceutical companies, and potential strategic partners. For more details about the event, including how to participate, see the official event page.

25 March 2026 | Økonomisk Ugebrev: Life Science Investor Conference
Copenhagen, Denmark
ExpreS2ion will participate in the Life Science Investor Conference hosted by Økonomisk Ugebrev in Copenhagen. The conference brings together listed and private life science companies with professional investors and analysts.

CFO Keith Alexander will provide a company update on ExpreS2ion, including its pipeline and platform technologies. For more details about the event, including how to participate, see the official event page.

Certified Adviser
Redeye Sweden AB

For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com

About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. ExpreS2ion Biotech AB is listed on Nasdaq First North Growth Market. For additional information, please visit www.expres2ionbio.com.